Ascentage Pharma
China-based clinical-stage biopharmaceutical company.
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 133 % | 650 % | 6 % | 342 % | (46 %) | 377 % | (34 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2668 %) | (365 %) | (343 %) | (24 %) | (145 %) | 37 % | 8 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2793 %) | (420 %) | (417 %) | (41 %) | (171 %) | 30 % | 3 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Ascentage Pharma is a global biopharmaceutical company that specializes in developing cutting-edge therapies for cancer and age-related diseases. The company operates in the pharmaceutical market, serving clients such as hospitals, clinics, and other healthcare providers. Their business model revolves around the research, development, and commercialization of innovative drugs.
Ascentage Pharma has secured exclusive global licensing rights for several patents related to PPI and cell apoptosis from the University of Michigan. This allows the company to develop and market unique therapies that can potentially revolutionize the treatment of various diseases.
In addition, the company has established strategic partnerships with renowned institutions like MD Anderson Cancer Center and Acerta Pharma. These collaborations involve preclinical and clinical research on compounds developed by Ascentage Pharma, such as APG-1252, APG-2575, APG-1387, APG-115, and HQP1351. These compounds are being studied for their potential in treating various types of cancer.
Ascentage Pharma also collaborates with UNITY Biotechnology to explore the development of molecules from their Bcl-2/Bcl-xL/ Mcl-1 inhibitor library for treating age-related diseases. This partnership allows Ascentage Pharma to validate patent combinations, enhance research capabilities, and expand commercialization rights to global markets and other therapeutic areas.
The company generates revenue through the sale of its approved drugs, licensing its patented technologies, and through strategic partnerships.
Keywords: Biopharmaceutical, Cancer Therapies, Age-Related Diseases, Drug Development, Global Licensing, Strategic Partnerships, Clinical Research, Patent Licensing, Revenue Generation, Global Market.